ERBB2 and gastric cancer: The patients treated with trastuzumab showed improvement of median overall survival (mOS,13.8 months vs. 11.1 months of chemotherapy alone) and overall response rate (ORR, 47% vs. 35% of chemotherapy alone), indicating that anti-HER2 therapy is a promising methods in treating gastric cancer.